COMMUNIQUÉS West-GlobeNewswire

IRIDEX Announces Infringement Lawsuit Against Quantel
09/01/2018
MOUNTAIN VIEW, Calif., Jan. 09, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX ) announced today that it has filed a lawsuit against Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. in the U.S. [...]
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
09/01/2018
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone resorption confirms [...]
CORRECTION: Axovant Announces Negative Results for Intepirdine in Phase 2b HEADWAY and Pilot Phase 2 Gait and Balance Studies; Positive Trends in Efficacy Seen in Pilot Phase 2 Nelotanserin Study
09/01/2018
BASEL, Switzerland, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXON ) today announced a correction to the data related to the Company’s investigational drug nelotanserin previously reported in its [...]
FDA Clears Pluristem’s Expanded Access Program to Initiate Treatments of Critical Limb Ischemia Outside of Ongoing Phase III Study
09/01/2018
Program Allows for Collection of Real-World Data Alongside the Company’s Ongoing Phase III Study in CLI FDA May Also Allow Pluristem to Be Compensated for the Cost of Treatment HAIFA, Israel, Jan. 09, 2018 (GLOBE [...]
Transactions in relation to share buyback program
09/01/2018
Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]
Genetic Technologies Regains Nasdaq Listing Compliance
09/01/2018
MELBOURNE, Australia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq: GENE ) (“Company”), is pleased to advise that the Company received a notification letter (the "Notice") from the [...]
Veritas Pharma Provides Comment on U.S. Attorney General Jeff Sessions Memo
09/01/2018
VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) and (Frankfurt: 2VP ) , (“Veritas” or the “Company”) provides the following statement to the memorandum issued by [...]
Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
09/01/2018
SURPASS is the first head-to-head superiority trial versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS)[1] EXCEED is the first head-to-head superiority trial versus Humira ® * in psoriatic arthritis ( [...]
Cannabis Wheaton Income Corp. Announces Strategic Investment and Alliance With Inner Spirit Holdings Ltd.
09/01/2018
VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX-V: CBW ) (" Wheaton Income " or the " Company ") is pleased to announce that it has entered into [...]
Breathtec Biomedical Unaware of Any Material Change
09/01/2018
VANCOUVER, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Breathtec Biomedical, Inc. (CSE:BTH) (OTCQB:BTHCF) (the “ Company ” or “ Breathtec ”) - at the request of the Investment Industry Regulatory Organization of [...]
Quotient Limited Reports Further Positive Data on its Initial Disease Screening Microarray and Provides Update on Blood Grouping
09/01/2018
Performance evaluation studies for the initial disease screening microarray demonstrate 100% sensitivity and >99% specificity for the CMV and Syphilis assays V&V for blood grouping is ongoing – pending a [...]
Cannabis Wheaton Income Corp. Announces Increase of Previously Announced Private Placement Financing of Convertible Debenture Units to up to $100 Million
09/01/2018
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION TO UNITED STATES VANCOUVER, British Columbia, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Cannabis Wheaton Income Corp. (d/b/a Wheaton Income) (TSX.V: [...]
BioSyent Announces Changes to Its Board of Directors
09/01/2018
TORONTO, Jan. 08, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”) (TSX Venture:RX) today announced the retirement of two long-serving Directors, Mr. Douglas Larson and Mr. Milton Wakefield, from its Board of [...]
Compass Cannabis Clinics and Starbuds Announce Canadian Joint Venture
08/01/2018
CALGARY, Alberta, Jan. 08, 2018 (GLOBE NEWSWIRE) -- 10330698 Canada Ltd. (dba Compass Cannabis Clinics (" Compass Cannabis " or the " Company ")) is pleased to announce that it has signed a binding letter agreement with [...]
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
08/01/2018
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for [...]
ConforMIS Reports Preliminary Fourth Quarter and Year-End 2017 Revenue Results; Provides 2018 Financial Guidance
08/01/2018
BILLERICA, Mass., Jan. 08, 2018 (GLOBE NEWSWIRE) -- ConforMIS, Inc. (NASDAQ: CFMS ), a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell [...]
Tabula Rasa HealthCare to Participate in the 20th Annual Needham Growth Conference
08/01/2018
MOORESTOWN, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Tabula Rasa HealthCare, Inc. (“TRHC”) (NASDAQ: TRHC ), a healthcare technology company optimizing medication safety by deploying new medication risk mitigation digital [...]
Sarepta Therapeutics Pre-Announces Fourth Quarter 2017 Revenue and Provides Full-Year 2018 Revenue Guidance for EXONDYS 51® (eteplirsen), Representing Approximately 100 Percent Year-over-Year Growth
08/01/2018
-- Fourth quarter 2017 EXONDYS 51 unaudited revenue of $57.3 million -- -- Full-year 2017 EXONDYS 51 unaudited revenue of $154.6 million -- -- Full-year 2018 EXONDYS 51 revenue guidance of $295 – $305 million -- -- 16 [...]
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
08/01/2018
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat patients with cancer and [...]

Pages